The Characterization and Classification of Receptors

References

• Himmelweit F. The Collected Papers of Paul Ehrlich, F. Himmelweit. Pergamon Press, London 1960; Vol 111, Chemotherapy
   Google Scholar
• Claudio T. Recombinant DNA technology in the study of ion channels. Trends Pharmacol Sci 1986; 7: 308–312
   Google Scholar
• De Jongh DK. Molecular Pharmacology: The Mode of Action of Biologically Active Compounds. A molecular approach to general pharmacology, EJ Ariens. Academic Press, New York 1964; I: 16
   Google Scholar
• Mills A, Duggan MJ. Orphan seven transmembrane domain receptors: reversing pharmacology. Trends Pharmacol Sci 1993; 14: 394–396
   PubMed Web of Science ®Google Scholar
• Meunier J-C, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour J-L, Guillemot J-C, Ferrara P, Monsarrat B, Mazarguil H, Vassart G, Parmentier M, Costentin J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1receptor. Nature 1995; 377: 532–534
   PubMed Web of Science ®Google Scholar
• Stephenson RP. Interaction of agonists and antagonists with their receptors. INSERM 1975; 50: 15–28
   Google Scholar
• Role LW. Diversity in primary structure and function of neuronal nicotinic acetylcholine receptor channels. Curr Opin Neurobiol 1992; 2: 254–262
   PubMedGoogle Scholar
• Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 1992; 256: 1217–1221
   PubMed Web of Science ®Google Scholar
• Schwartz TW. Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 1994; 5: 434–444
   PubMedGoogle Scholar
• Giros B, Sokoloff P, Martres M-P, Riou J-F, Emorine LJ, Schwartz JC. Alternative splicing directs the expression of two D2dopamine receptor isoforms. Nature 1989; 342: 923–926
   PubMed Web of Science ®Google Scholar
• Epelbaum J, Dournaud P, Fodor M, Viollet C. The neurobiology of somatostatin. Crit Rev Neurobiol 1994; 8: 25–44
   PubMedGoogle Scholar
• Downie DL, Hope AG, Lambert JJ, Peters JA, Blackburn TP, Jones BJ. Pharmacological characterization of the apparent splice variants of the murine 5-HT3R-A subunit expressed in xenopus laevis oocytes. Neuropharmacology 1994; 33: 473–482
   PubMed Web of Science ®Google Scholar
• Gerald C, Adham N, Kao H-T, Olsen MA, Laz TM, Schechter LE, Bard JA, Vaysse PJ-J, Hartig PR, Branchek TA, Weinshank RL. The 5-HT4receptor: molecular cloning and pharmacological characterization of two splice variants. EMBO J 1995; 14: 2806–2815
   PubMed Web of Science ®Google Scholar
• Simon J, Kidd EJ, Smith FM, Chessell IP, Murrell-Lagnado R, Humphrey PPA, Barnard EA. Localization and functional expression of splice variants of the P2X2receptor. Mol Pharmacol 1997; 52: 237–248
   Google Scholar
• Humphrey PPA. The characterization and classification of neurotransmitter receptors, DG Trist, PPA Humphrey, P Lett, NP Shankley. NY Acad Sci. 1997; 812: 1–13
   Google Scholar
• Regoli D, Boudon A, Fauchere J-C. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 1994; 46: 551–599
   PubMed Web of Science ®Google Scholar
• Birnbaumer L, Abramowitz J, Yatani A, Okabe K, Mattera R, Graf R, Sanford J, Codina J, Brown AM. Roles of G proteins in coupling of receptors to ionic channels and other effector systems. Crit Rev Biochem Mol Biol 1990; 25: 225–244
   Web of Science ®Google Scholar
• Oksenberg GD, Marsters SA, O'Dowd BF, Jin H, Havlik S, Peroutka SJ, Ashkenazi A. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1Breceptors. Nature 1992; 360: 161–163
   PubMed Web of Science ®Google Scholar
• Gether U, Johansen TE, Snider RM, Lowe JA, Nakanishi S, Schwartz TW. Different binding epitopes on the NK1receptor for substance P and a nonpeptide antagonist. Nature 1993; 362: 345–347
   PubMed Web of Science ®Google Scholar
• Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 1993; 16: 299–321
   PubMed Web of Science ®Google Scholar
• Sargent PB. The diversity of neuronal nicotinic receptors. Annu Rev Neurosci 1993; 16: 403–443
   PubMed Web of Science ®Google Scholar
• Ahlquist RP. A study of the adrenergic receptors. Am J Physiol 1948; 153: 586–600
   PubMed Web of Science ®Google Scholar
• Nickerson M. The pharmacology of adrenergic blockade. Pharmacol Rev 1949; 1: 27–101
   Web of Science ®Google Scholar
• Black JW, Stephenson JS. Pharmacology of a new adrenergicβ-receptor blocking compound. Lancet 1962; 2: 311–314
   PubMed Web of Science ®Google Scholar
• Doxey JC, Smith CFC, Walker JM. Selectivity of blocking agents for pre- and postsynapticα-adrenoceptors. Br J Pharmacol 1977; 60: 91
   PubMed Web of Science ®Google Scholar
• Black JW. The Heyman Institute of Pharmacology. Development of ideas about noradrenaline receptors, AF De Schaepdryver. Heymans Foundation, GhentBelgium 1990; 115, 1890–1990
   Google Scholar
• Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG, Jr. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214: 597–598
   PubMed Web of Science ®Google Scholar
• Frielle T, Daniel KW, Caron MG, Lefkowitz RJ. The structural basis ofβ-adrenergic receptor subtype specificity: studies with chimericβ1/β2-adrenergic receptor. Proc Natl Acad Sci USA 1988; 85: 9494–9498
   PubMed Web of Science ®Google Scholar
• Ash ASF, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol 1966; 27: 427–439
   PubMed Web of Science ®Google Scholar
• Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H2-receptors. Nature 1972; 236: 385–390
   PubMed Web of Science ®Google Scholar
• Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M, Schunack W, Schwartz JC. Highly potent and selective ligands for histamine H3-receptors. Nature 1987; 327: 117–123
   PubMed Web of Science ®Google Scholar
• Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA. VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994a; 46: 157–203
   PubMed Web of Science ®Google Scholar
• Coleman RA, Smith WL, Narumiya S. VIII. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205–229
   PubMed Web of Science ®Google Scholar
• Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M. VI. International Union of Pharmacology nomenclature and classification of purinoceptors. Pharmacol Rev 1994; 46: 143–156
   PubMed Web of Science ®Google Scholar
• Humphrey PPA. Peripheral 5-hydroxytryptamine receptors and their classification. Neuropharmacology 1984; 23: 1503–1510
   Google Scholar
• Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986; 25: 563–576
   PubMed Web of Science ®Google Scholar
• Humphrey PPA, Hartig P, Hoyer D. A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 1993; 14: 233–236
   PubMed Web of Science ®Google Scholar
• Martin GR, Humphrey PPA. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 1994; 33: 261–273
   PubMed Web of Science ®Google Scholar
• Hartig PR, Hoyer D, Humphrey PPA, Martin GR. Alignment of receptor nomenclature with the human genome: classification of 5-HT1Band 5-HT1Dreceptor subtypes. Trends Pharmacol Sci 1996; 17: 103–105
   PubMed Web of Science ®Google Scholar
• Hartig PR, Branchek TA, Weinshank RL. A subfamily of 5-HT1Dreceptor genes. Trends Pharmacol Sci 1992; 13: 152–159
   PubMed Web of Science ®Google Scholar
• Sachais BS, Snider RM, Lowe Ja, III, Krause JE. Molecular basis for the species selectivity of the substance P antagonist CP-96,345. J Biol Chem 1993; 268: 2319–2323
   PubMed Web of Science ®Google Scholar
• Adham N, Tamm JA, Salon JA, Vaysse PJ-J, Weinshank RL, Branchek TA. A single point mutation increases the affinity of serotonin 5-HT1Dα5-HT1Dβ5-HT1Eand 5-HT1Freceptors forβ-adrenergic antagonists. Neuropharmacology 1994; 33: 387–391
   PubMed Web of Science ®Google Scholar
• Humphrey PPA, Spedding M, Vanhoutte PM. Receptor classification and nomenclature: the revolution and the resolution. Trends Pharmacol Sci 1994; 15: 203–204
   PubMed Web of Science ®Google Scholar
• Furchgott RF. The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory, H Blaschko, E Muscholl. Springer Verlag, Berlin 1972; 33: 283–335, Catecholamines. Handbook Exp Pharmac NS
   Google Scholar
• Humphrey PPA. Pharmacological characterisation of cardiovascular 5-hydroxytryptamine receptors. Vascular Neuroeffector Mechanisms, IVth International Symposium, JA Bevan, et al. Raven Press, New York 1983; 237–242, Chapter 17
   Google Scholar
• Kenakin TP. The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev 1984; 36: 165–222
   PubMed Web of Science ®Google Scholar
• Kenakin TP. Challenges for receptor theory as a tool for drug and drug receptor classification. Trends Pharmacol Sci 1989; 10: 18–22
   Google Scholar
• Kenakin TP, Bond RA, Bonner TI. Definition of pharmacological receptors. Pharmacol Rev 1992; 44: 351–362
   PubMed Web of Science ®Google Scholar
• Schwarz RD, Davis RE, Jaen JC, Spencer CJ, Tecle H, Thomas AJ. Characterization of muscarinic agonists in recombinant cell lines. Life Sci 1993; 52(5–6)465–472
   Google Scholar
• Richards MH, Van Giersbergen PL. Differences in agonist potency ratios at human M1muscarinic receptors expressed in A9L and CHO cells. Life Sci 1995; 57(4)397–402
   Google Scholar
• Kenakin T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 1996; 48: 413–463
   PubMed Web of Science ®Google Scholar
• Bockaert J, Brand C, Journot L. Do recombinant receptor assays provide affinity and potency estimates?, DG Trist, PPA Humphrey, P Lett, NP Shankley. NY Acad Sci. 1997; 812: 55–70
   Google Scholar
• Jackson T. Structure and function of G protein coupled receptors. Pharmacol Ther 1991; 50: 425–442
   PubMedGoogle Scholar
• Milligan G. Mechanisms of multifunctional signaling by G protein-linked receptors. Trends Pharmacol Sci 1993; 14: 239–244
   PubMed Web of Science ®Google Scholar
• Watson S, Arkinstall S. The G-Protein Linked Receptor. Factsbook. Academic Press, Orlando, FL 1994
   Google Scholar
• Kenakin T. Agonist-receptor efficacy. I. Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 1995; 16: 188–192
   PubMed Web of Science ®Google Scholar
• Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 1995; 16: 232–238
   PubMed Web of Science ®Google Scholar
• Kleuss C, Scherubl H, Hescheler J, Schultz G, Wittig B. Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. Science 1993; 259: 832–834
   PubMed Web of Science ®Google Scholar
• Vallar L, Muca C, Magni M, Albert P, Bunzow J, Meldolesi J, Civelli O. Differential coupling of dopaminergic D2receptors expressed in different cell types. J Biol Chem 1990; 265: 10320–10326
   PubMed Web of Science ®Google Scholar
• Birnbaumer L, Birnbaumer M. Signal transduction by G proteins. J Rec Sig Trans Res 1994; 15: 213–252
   Google Scholar
• Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993; 365: 170–175
   PubMed Web of Science ®Google Scholar
• Castro SW, Buell G, Feniuk W, Humphrey PPA. Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst1and sst2in mouse fibroblast (Ltk-) cells. Br J Pharmacol 1996; 117: 639–646
   Google Scholar
• Stephenson RP. A modification of receptor theory. Br J Pharmacol 1956; 11: 379–393
   PubMed Web of Science ®Google Scholar
• Probst WC, Snyder LA, Schuster DI, Brosius J, Sealfon SC. Sequence alignment of the G-protein coupled receptor superfamily. DNA Cell Biol 1992; 11: 1–20
   PubMed Web of Science ®Google Scholar
• Lewis C, Neidhart S, Holy C, North RA, Buell G, Surprenant A. Coexpression of P2X2and P2X3receptor subunits can account for ATP-gated currents in sensory neurons. Nature 1995; 377: 432–435
   PubMed Web of Science ®Google Scholar
• Dohlman H, Caron M, Lefkowitz RJ. A family of receptors coupled to guanine nucleotide regulating proteins. Biochemistry 1987; 26: 2657–2664
   PubMed Web of Science ®Google Scholar
• Hall JM, Caulfield MP, Watson SP, Guard S. Receptor subtypes or species homologues: relevance to drug discovery. Trends Pharmacol Sci 1993; 14: 376–383
   PubMed Web of Science ®Google Scholar
• Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PPA, O'Carroll A-M, Patel YC, Schonbrunn A, Taylor JE, Reisine T. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86–88
   PubMed Web of Science ®Google Scholar
• Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocrine Rev 1995; 16: 427–442
   PubMed Web of Science ®Google Scholar
• Hoyer D, LÜBbert H, Bruns C. Molecular pharmacology of somatostatin receptors. Naunyn-Schmiedeberg's Arch Pharmacol 1994b; 350: 441–453
   Google Scholar
• Caulfield MP. Muscarinic receptors—characterization coupling and function. Pharmacol Ther 1993; 58(3)319–379
   PubMed Web of Science ®Google Scholar
• Wess J. Molecular basis of muscarinic acetylcholine receptor function. Trends Pharmacol Sci 1993; 14: 308–313
   PubMed Web of Science ®Google Scholar
• Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, Trendelenburg U. IV. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994; 46: 121–136
   PubMed Web of Science ®Google Scholar
• Narumiya S. Prostanoid receptors and signal transduction. Prog Brain Res 1996; 113: 231–241
   Google Scholar
• Vanetti M, Vogt G, Hollt V. The two isoforms of the mouse somatostatin receptor (mSSTR2A) and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization. FEBS Lett 1993; 331: 260–266
   PubMed Web of Science ®Google Scholar
• Offermanns S, Wieland T, Homann D, Sandmann J, Bombien E, Spicher K, Schultz G, Jakobs KH. Transfected muscarinic acetylcholine receptors selectively couple to G1-type G proteins and Gq/11. Mol Pharmacol 1994; 45: 890–898
   PubMed Web of Science ®Google Scholar
• Gilman AG. G proteins and regulation of adenylyl cyclase. Biosci Rep 1995; 15: 65–97
   PubMed Web of Science ®Google Scholar
• Schwartz TW, Gether U, Schambye HT, Hjorth SA. Molecular mechanism of action of non-peptide ligands for peptide receptors. Curr Pharm Design 1995; 1: 325–342
   Google Scholar
• Vanhoutte PM, Humphrey PPA, Spedding M. X. International Union of Pharmacology Recommendations for nomenclature of new receptor subtypes. Pharmacol Rev 1996; 48: 1–2
   PubMed Web of Science ®Google Scholar